136 results about "Citrulline" patented technology

The present invention relates to the fields of medicine and cosmetology, and discloses a cell active peptide composition that promotes the regeneration of multi-type collagen structural proteins, its preparation method, and its application in medicine and cosmetology. The composition uses raw materials such as tripeptide-10 citrulline, hexapeptide-9, hydrolyzed sodium hyaluronate, γ-aminobutyric acid, decarboxylated carnosine hydrochloride, acetyl tetrapeptide-3, acetyl tetrapeptide-11, palmitoyl dipeptide-7, and palmitoyl pentapeptide-4. The composition can promote the coordinated expression of skin type I, type III, type IV, type VII, type XVII collagen, fibronectin, elastin, and glycosaminoglycans; prevent collagen cross-linking, maintain triple helix structure, and inhibit collagen degradation. Applied to dermatology and cosmetology, it can accelerate the regeneration of structural proteins such as skin collagen, repair skin damage, reduce wrinkles such as crow's feet, tear groove lines, nasolabial folds, and under-eye lines, solve the skin aging problem caused by the loss of structural proteins such as collagen, and improve skin elasticity and firmness.

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

The embodiment of the invention discloses a composition with an anti-UVB damage function, a skin care product and application. The composition and the skin care product can be used for solving the anti-UVB damage problem. The composition comprises: a first compound selected from a compound represented by a formula (I) or a formula (II); and a second compound, wherein the second compound is selected from any one of palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4.

The embodiment of the invention discloses a teprenone-containing composition, a skin care product and application. The teprenone-containing composition and the skin care product can promote the expression of CD44. The composition containing the teprenone is prepared from the teprenone and acetyl tripeptide-30 citrulline, and the mass ratio of the teprenone to the acetyl tripeptide-30 citrulline is 50 to (15 to 25).

The invention discloses an analysis method for determining multiple components of white spirit by high performance liquid chromatography-tandem mass spectrometry, and relates to the technical field of white spirit analysis and detection, and the analysis method comprises the following steps: firstly, preparing an ethyl carbamate precursor substance standard stock solution and a mixed standard intermediate solution, and diluting the mixed standard intermediate solution step by step to obtain a mixed standard working solution; then determining chromatographic and mass spectrometry conditions, wherein BEH Ami chromatographic column is adopted as the chromatographic condition, and 0.1% formic acid water-acetonitrile is adopted as a mobile phase for gradient elution; a mass spectrum condition adopts a multi-reaction monitoring mode under an electrospray positive ion mode; drawing a quantitative calibration curve; finally, preparing a to-be-detected sample for content determination. According to the analysis method for determining the multiple components of the Baijiu through the high performance liquid chromatography-tandem mass spectrometry, through chromatographic condition optimization and mass spectrometry parameter innovation, the detection efficiency is improved, peak area data of urea, citrulline and arginine can be synchronously obtained through single sample injection, the analysis time is short, and quantification is accurate.

There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.

A solid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is citrulline, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the solid supplement composition comprises an amount of nitrate ion (NO3—) that is at least 0.33125 mg.

The invention discloses application of a marker in preparation of a sicca syndrome diagnosis product, and a construction method and equipment of a diagnosis model, and relates to the technical field of sicca syndrome diagnosis. The sicca syndrome marker comprises a ratio of citrulline to arginine. The ratio of citrulline to arginine in serum has a close relationship with sicca syndrome, a diagnostic model developed based on the marker has the technical advantages of high diagnostic specificity, high sensitivity and good accuracy, and the detection method is simple, convenient and reliable and is easy to clinically popularize.

The present invention relates to a Corynebacterium glutamicum mutant strain having increased L-citrulline productivity, and a method of producing L-citrulline using the same. The Corynebacterium glutamicum mutant strain is capable of producing L-citrulline in high yield and high concentration while inhibiting the production of by-products, because the activity of the protein that is expressed by the NCgl2657 gene therein has been weakened or inactivated.

The application provides an arginine deiminase mutant with alkali resistance, and the amino acid sequence of the mutant is SEQ ID NO:3. When L-arginine is used as a substrate to synthesize L-citrulline, the pH value of a reaction system can be as high as pH 11 or higher, and hydrochloric acid neutralization is not needed, so that the cost of product separation and purification and waste water treatment is significantly reduced.

The invention discloses a firming and anti-aging composition containing a Campania acuta bark extract and application of the firming and anti-aging composition, and belongs to the technical field of cosmetics. The firming and anti-aging composition containing the Campanumoea maculata bark extract comprises the following components: the Campanumoea maculata bark extract, a Flos Magnoliae Officinalis extract, a Tremella aurantialba extract and a composite polypeptide, and the composite polypeptide is composed of carnosine, acetyl tetrapeptide-5 and tripeptide-10 citrulline in a mass ratio of 1: (0.4-0.6): (0.2-0.6). Through the synergistic effect of the four components, the firming and anti-aging composition has a good effect of inhibiting the activity of elastase and collagenase.

The present disclosure relates to a composition for use in preventing and / or treating renal failure, such as uremia, in a subject. Said composition is a composition for oral consumption and comprises i) an extract of Rhodiola rosea root, ii) L-arginine, iii) L-citrulline; and iv) an extract of beet root. Said composition is also useful for preventing or reducing a gain of body weight, or for reducing body weight, in a subject in need thereof.

Provided herein is a methods for monitoring inflammatory disease activity in a subject comprising: (i) obtaining a sample from the subject; and (ii) measuring an autoantibody concentration in the sample using an immunoassay. Optionally, the inflammatory disease is rheumatoid arthritis (RA). Optionally, the autoantibody is an anti-citrullinated vimentin autoantibody (anti-Sa) or an anti-carbamylated protein autoantibody (anti-CarP). Optionally, the autoantibody concentration is correlated to a multi-disease biomarker activity (MBDA) score. Also provided herein are systems and kits for performing the method described herein.

To provide a composition for improving blood vessel repair function using cells.SOLUTION: This composition for improving blood vessel repair function comprises: at least one selected from the group consisting of astaxanthin, glucosamine hydrochloride, chondroitin sulfate, tocopherol, resveratrol, hesperidin (vitamin P), beta-carotene, ubiquinone, lipoic acid, zinc, arsine, arginine, citrulline, taurine, vitamin E, and mucin; and stem cells.SELECTED DRAWING: Figure 1

A heart boosting formulation comprises: L-carnitine, alpha-linolenic acid, citrulline, vitamin D3, lycopene, holy basil, cinnamon and beetroot.

To provide a new bitterness masking agent of potassium chloride, and to provide a production method or the like including the masking agent.SOLUTION: The bitterness masking agent of potassium chloride contains Balsam Peru essential oil as an active ingredient. Here, it is preferable to further contain at least one or more selected from the group consisting of arginine, glutamic acid, lysine and citrulline. It is also preferable to further contain at least one selected from the group consisting of acetoin, diacetyl, and 2, 3-pentanedione.SELECTED DRAWING: None

The present invention relates to citrullinated Cytokeratin peptides that can be used in cancer immunotherapy. The modified peptides may be used as vaccines or as targets for T cell receptor (TCR) and adoptive T cell transfer therapies. Such vaccines or targets may be used in the treatment of cancer.

To provide a citrulline-reducing agent for intraoral use.SOLUTION: The present invention provides a citrulline-reducing agent for intraoral use that contains vitamin B6. The citrulline-reducing agent for intraoral use inhibits citrulline production and / or secretion by intraoral bacteria such as those belonging to Porphyromonas, Fusobacterium, Prevotella, Veillonella, Treponema, or Streptococcus.SELECTED DRAWING: None

The invention discloses a promethazine hydrochloride injection and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. Every 1 mL of the promethazine hydrochloride injection is prepared from the following raw materials and auxiliary materials: 20 to 30 mg of promethazine hydrochloride, 0.3 to 0.8 mg of anhydrous sodium sulfite, 0.5 to 1.5 mg of sodium pyrosulfite, 0.02 to 0.08 mg of citrulline, 0.02 to 0.05 mg of gallic acid and the balance of water for injection. The stability of the promethazine hydrochloride injection can be improved, the impurity content can be reduced, and it can be guaranteed that bacterial endotoxin meets the production requirement in the long-term storage process.

The invention relates to a set of diagnostic markers comprising glutamic acid, glutamine, glycine, tryptophan, proline, threonine, citrulline, aspartic acid, and asparagine, for use in diagnosing breast cancer, and to an in vitro method for diagnosing breast cancer.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The invention provides application of lactobacillus reuteri to improvement of prostatitis and erectile dysfunction. The bacterial strain is lactobacillus reuteri NHNK-2001, the lactobacillus reuteri NHNK-2001 is preserved in the China Center for Type Culture Collection on April 25, 2024, and the preservation number of the lactobacillus reuteri NHNK-2001 is CCTCC (China Center for Type Culture Collection) NO: M 2024800. The NHNK-2001 has the functions of generating L-citrulline, repairing aged vascular endothelial cells, promoting vasodilation, repairing aged prostate cells and reducing prostatitis, and can be used for preparing products for improving prostatitis and erectile dysfunction.

The present invention relates to a gene variant of the transcriptional regulator LysG and a method for producing L-citrulline or L-arginine using same. The gene variant of the transcriptional regulator LysG according to the present invention has protein activity that is altered due to the mutation of one or more bases in the base sequence of a gene encoding the transcriptional regulator LysG, and thus, it is possible to effectively produce L-citrulline or L-arginine from a recombinant microorganism comprising the variant.

A micronutrient composition comprises of several combinations of individual ingredients in forming Mix 11, G12, G13 and core mix formulation. Core mix contains magnesium citrate, alpha-Ketoglutaric acid, L-Citrulline and Taurine. The Mix 11, G12 and G13 contains Magnesium Citrate, Alpha-Ketoglutaric Acid, Niacinamide, L-Glutamine, L-Citrulline, Sodium Pyruvate, Succinic acid, Vitamin B complex, Taurine, L-Cysteine, L-Methionine, L-Ascorbic Acid, Coenzyme Q10 or combination thereof. A method of administering and treating a specific disease which is due to one of an oxidative stress, impaired mitobiogenesis and ATP production in a mammal is disclosed.

The invention belongs to the technical field of biological medicines, and particularly discloses an application of L-citrulline (L-citrulline, Cit) in preparation of a medicine for preventing or treating tuberculosis. The invention provides application of L-citrulline in preparation of medicines for preventing or treating tuberculosis. The invention provides a medicine for preventing or treating tuberculosis. The medicine comprises L-citrulline. The invention discloses application of L-citrulline in preparation of drugs for preventing or treating tuberculosis, the L-citrulline can significantly reduce the bacterial load after mycobacterium marinum infection and prolong the survival time of zebra fish, and the L-citrulline has the prospect of being developed into related drugs for preventing and treating tuberculosis.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

The invention provides a method for simultaneously detecting the content of arginine and citrulline by high performance liquid chromatography. According to the method, high performance liquid chromatography is adopted for detection, and chromatographic conditions are as follows: a zwitter-ion HILIC chromatographic column and an ultraviolet detector are used, a mixed solution of a monopotassium phosphate buffer solution and methanol is used as a mobile phase, and the content of arginine and citrulline is detected. The high performance liquid chromatography detection method does not need derivation, can accurately detect the content of arginine and citrulline at the same time, is short in detection time, good in separation degree of arginine and citrulline, good in peak shape symmetry and high in accuracy, and can meet the detection requirements in the actual production process.

This invention discloses an anhydrous deoxidizer, comprising, by weight, 10-20 parts of a hydroxyl-terminated polybutadiene-maleic anhydride compound, 10-20 parts of modified zeolite, 15-25 parts of modified silica gel, and 45-55 parts of polyethylene terephthalate. The modified silica gel is prepared from silica gel, sorbitol, bis(3-triethoxysilanepropyl) carbonate, and alumina. The modified zeolite is prepared from zeolite, 1-chloroethylcyclohexyl carbonate, maleimide-L-valine-L-citrulline-p-aminobenzyl alcohol, and N,N-dimethylformamide. The anhydrous deoxidizer provided by this invention exhibits excellent deoxidation performance and efficiency.

The invention discloses a citric acid fentanyl injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The formula of the citric acid fentanyl injection comprises an active ingredient citric acid fentanyl, a pH buffering agent, a compound stabilizer, an isoosmotic adjusting agent and solvent water for injection, the compound stabilizer is composed of sodium thiosulfate, citrulline and methyl meglumine, and the sodium thiosulfate, the citrulline and the methyl meglumine cooperate to inhibit degradation of citric acid fentanyl citrate. Through a specific compound stabilizer system and an optimized preparation process, the stability, the dissolution efficiency and the quality uniformity of the injection are remarkably improved, the process steps are clear, parameters are definite, and the injection is suitable for large-scale production and has important clinical value and industrial significance.

The invention discloses an edible whey protein film loaded with amino acids and its preparation method and application, wherein the whey protein film is prepared by film-forming treatment of a film-forming liquid comprising whey protein, a nutrient enhancer, glycerol and water, wherein the nutrient enhancer is a non-protein amino acid; the whey protein film preparation method is as follows: (1) whey protein is dissolved in water, and water bath treatment is performed after adjusting pH with an alkaline solution, and cooling is taken out after termination to obtain an alkaline whey protein solution; (2) glycerol and a nutrient enhancer are added to the above solution, and the mixture is stirred until completely dissolved to obtain a film-forming liquid; (3) the film-forming liquid is subjected to a film-forming treatment to obtain an edible whey protein film. The present invention adds physiologically active L-taurine, L-theanine or L-citrulline to a whey protein solution to prepare an edible whey protein film having significantly improved mechanical properties, swelling properties, air permeability, solubility and thermoplasticity, thereby achieving a common improvement in the processing functionality and nutritional functionality of the whey protein film.